PODCAST BY: SORAH YOON
FOR ARTICLE DETAILS, PLEASE VISIT: http://www.eurekaselect.com/162489
Tag: therapeutics.
TESTIMONIAL BY PUSHPENDER K. SHARMA!
Contributed Article: “Clinical, Prognostic and Therapeutic Significance of Heat Shock Proteins in Cancer“
Editor’s Choice – “Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?”
Journal: Current Alzheimer Research
Author(s): Parul Bali, Debomoy K. Lahiri, Avijit Banik, Bimla Nehru and Akshay Anand
Abstract:
Alzheimer’s disease (AD) is one of the most common causes of dementia. Despite several decades of research in AD, there is no standard disease- modifying therapy available and currentlyapproved drugs provide only symptomatic relief. Stem cells hold immense potential to regenerate damaged tissues and are currently tested in some brain-related disorders, such as AD, amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). We review stem cell transplantation studies using preclinical and clinical tools. We describe different sources of stem cells used in various animal models and explaining the putative molecular mechanisms that can rescue neurodegenerative disorders. The clinical studies suggest safety, efficacy and translational potential of stem cell therapy. The therapeutic outcome of stem cell transplantation has been promising in many studies, but no unifying hypothesis can convincingly explain the underlying mechanism. Some studies have reported paracrine effects exerted by these stem cells via the release of neurotrophic factors, while other studies describe the immunomodulatory effects exerted by the transplanted cells. There are also reports which indicate that stem cell transplantation might result in endogenous cell proliferation or replacement of diseased cells. In animal models of AD, stem cell transplantation is also believed to increase expression of synaptic proteins.
Read more here: http://benthamscience.com/journals/current-alzheimer-research/volume/14/issue/2/page/208/
Editor’s Choice – “Spinal Muscular Atrophy: More than a Disease of Motor Neurons?”
Journal: Current Molecular Medicine
Author(s): L. A. Nash, J. K. Burns, J. Warman Chardon, R. Kothary and R J Parks
Abstract:
Spinal muscular atrophy (SMA) is the most common genetically inherited neurodegenerative disease resulting in infant mortality. SMA is caused by genetic deletion or mutation in the survival of motor neuron 1 (SMN1) gene, which results in reduced levels of the survival of motor neuron (SMN) protein. SMN protein deficiency preferentially affects α- motor neurons, leading to their degeneration and subsequent atrophy of limb and trunk muscles, progressing to death in severe forms of the disease. More recent studies have shown that SMN protein depletion is detrimental to the functioning of other tissues including skeletal muscle, heart, autonomic and enteric nervous systems, metabolic/endocrine (e.g. pancreas), lymphatic, bone and reproductive system. In this review, we summarize studies discussing SMN protein’s function in various cell and tissue types and their involvement in the context of SMA disease etiology. Taken together, these studies indicate that SMA is a multi-organ disease, which suggests that truly effective disease intervention may require body-wide correction of SMN protein levels.
Read more here: http://benthamscience.com/journals/current-molecular-medicine/volume/16/issue/9/page/779/
SMI Event – 8th annual RNA Therapeutics conference 2017!
SMi Group announces the return of its 8th annual RNA Therapeutics conference to London on the 22nd – 23rd of February 2017.
SMi’s 8th annual RNA Therapeutics conference will feature a mix of case study-led presentations, panel debates, interactive workshops and keynote addresses tailored for an audience of professionals and research scientists looking to develop and commercialise novel RNA therapeutics and delivery systems. This exciting programme for 2017 will showcase new developments through clinical and pre-clinical results in topics such as: messenger RNA-based therapeutics, anti-sense oligonucleotides and new sites for RNA silencing.
Join us next February to expand your scientific horizons on emerging concepts in nanoparticle delivery systems, small activating RNA and 3rd generation antisense technology. Plus, we’ll be honing in on under-met areas such as targeted delivery beyond the liver, and offering regulatory guidance on the reporting of clinical data through an exclusive MHRA keynote.
Featured speakers include:
- Nagy Habib, Head of Surgery, Co-Founder, Imperial College Healthcare NHS Trust, MiNA Therapeutics
- John Johnston, Clinical Assessor Biologicals & Biotechnology Unit, MHRA
- Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech RNA Pharmaceuticals
- Bo Rode Hansen, Global Head of RNA Therapeutics, Roche
- Nicole Meisner-Kober, Senior Investigator, RNA Biology, Novartis Institutes for Biomedical Research
- Steve Hood, Director, Bioimaging, GSK
- David Giljohann, CEO, Exicure
- Shai Erlich, Chief Medical Officer & President USA, Quark Pharmaceuticals Inc
- Amotz Shemi, CEO, Silenseed
- Sanyogitta Puri, Associate Principal Scientist, AstraZeneca
For further details visit the website at http://www.therapeutics-rna.com/bentham
Related Journal: Current Pharmaceutical Design
Bentham Science 
You must be logged in to post a comment.